Indivior PLC (INDV) Stock Analysis

Why this analysis is different

• A sector-relative MoonshotScore — five pillars (business quality, financial safety, valuation, growth durability, momentum) re-ranked nightly against the full universe of US-listed common stocks.
• An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
• Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.

Indivior PLC (INDV) Healthcare & Pipeline Overview

Indivior Pharmaceuticals Inc. specializes in buprenorphine-based treatments for opioid dependence, operating across the United States, United Kingdom, and other global markets. With a strong gross margin of 83.1% and a focus on addiction treatment, Indivior competes in the specialty pharmaceutical sector against companies like Amneal Pharmaceuticals and Lantheus Holdings.

What Is the Investment Thesis for INDV?

With a P/E ratio of 12.15 and a strong gross margin of 83.1%, the company demonstrates financial stability and profitability. Key value drivers include the ongoing demand for opioid dependence treatments and Indivior's established market presence with products like Suboxone Film. Growth catalysts involve expanding its product pipeline to address co-occurring disorders and other substance use disorders. Potential risks include regulatory challenges, competition from generic alternatives, and evolving treatment paradigms. The company's beta of 1.21 suggests higher volatility compared to the market. Indivior's focus on a critical healthcare need, combined with its financial performance, supports a positive investment outlook, contingent on managing regulatory and competitive pressures.

Based on FMP financials and quantitative analysis

INDV Key Highlights

Market Cap of $4.27B reflects Indivior's significant valuation in the specialty pharmaceutical sector.

• P/E Ratio of 12.15 indicates the company's earnings relative to its stock price, suggesting a reasonable valuation compared to industry peers.
• Profit Margin of 19.4% demonstrates Indivior's ability to generate profit from its revenue, highlighting operational efficiency.
• Gross Margin of 83.1% showcases Indivior's strong pricing power and cost management in its product offerings.
• Beta of 1.21 suggests that Indivior's stock is more volatile than the market average, potentially offering higher returns but also greater risk.

Who Are INDV's Competitors?

INDV is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.

AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance This table mixes two scoring engines — compare a number only with others carrying the same tag.

What Are INDV's Key Strengths?

Specialization in buprenorphine-based opioid dependence treatments.

• Established market presence and brand recognition.
• High gross margin indicating strong pricing power.
• Global operations with a presence in key markets.

What Are INDV's Weaknesses?

Reliance on a limited number of products.

• Exposure to generic competition.
• Regulatory risks and potential litigation.
• Dependence on the opioid dependence treatment market.

What Could Drive INDV Stock Higher?

Potential FDA approval of new formulations or indications for existing products.

• Expansion of geographic reach into new markets with high unmet needs for addiction treatment.
• Development and launch of digital health solutions to improve patient adherence and outcomes.
• Strategic partnerships with healthcare providers and advocacy groups to increase awareness and access to treatment.

What Are the Key Risks for INDV?

Insider selling — insiders were net sellers of roughly $26.2M recently.

• Increasing competition from generic alternatives to Suboxone Film.
• Changes in regulatory policies and treatment guidelines that could impact market access.
• Product liability claims related to the use of buprenorphine-based medications.
• Dependence on the opioid dependence treatment market, which is subject to evolving treatment paradigms.

What Are the Growth Opportunities for INDV?

• Expanding Product Pipeline: Indivior has the opportunity to develop new formulations and treatments for opioid dependence and co-occurring disorders. The market for addiction treatment is projected to reach $15 billion by 2028, driven by increasing awareness and government initiatives. By investing in research and development, Indivior can introduce innovative therapies that address unmet needs and capture a larger share of the market. This includes exploring treatments for other substance use disorders and mental health conditions that often accompany addiction, providing a holistic approach to patient care.
• Geographic Expansion: Indivior can expand its presence in international markets, particularly in regions with high rates of opioid abuse and limited access to treatment. The global market for opioid dependence treatment is expected to grow at a CAGR of 6% over the next five years. By establishing partnerships and distribution networks in key regions, Indivior can increase its revenue and diversify its geographic footprint. This includes targeting emerging markets in Asia and Latin America, where the demand for addiction treatment is growing rapidly.
• Strategic Partnerships: Indivior can collaborate with healthcare providers, advocacy groups, and government agencies to improve access to addiction treatment and promote awareness of its products. By forming strategic alliances, Indivior can enhance its reputation and build trust with key stakeholders. This includes partnering with hospitals and clinics to integrate Indivior's medications into their treatment protocols, as well as working with patient advocacy groups to raise awareness of the benefits of buprenorphine-based therapy.
• Digital Health Solutions: Indivior can leverage digital health technologies to enhance patient engagement and improve treatment outcomes. The market for digital health solutions in addiction treatment is projected to reach $5 billion by 2027, driven by the increasing adoption of telehealth and mobile health apps. By developing digital tools that support medication adherence, provide remote monitoring, and offer virtual counseling, Indivior can improve patient outcomes and reduce healthcare costs. This includes developing mobile apps that track medication use, provide educational resources, and connect patients with support groups.
• Addressing Co-occurring Disorders: Indivior can focus on developing treatments for co-occurring mental health disorders, such as depression and anxiety, which often accompany opioid dependence. By integrating mental health treatments into its product portfolio, Indivior can offer a more comprehensive approach to patient care and address the complex needs of individuals struggling with addiction and mental health issues.

What Are INDV's Competitive Advantages?

• Proprietary formulations of buprenorphine-based medications.
• Established market presence and brand recognition in the addiction treatment space.
• Strong relationships with healthcare providers and pharmacies.
• Regulatory approvals and patents that protect its products from generic competition.

What Does INDV Do?

Indivior Pharmaceuticals Inc. is a global pharmaceutical company focused on developing, manufacturing, and selling treatments for opioid dependence and related substance use disorders. Founded on September 26, 2014, and headquartered in North Chesterfield, Virginia, Indivior emerged as a dedicated entity committed to addressing the opioid crisis. The company's core products are buprenorphine-based medications, including Suboxone Film, Suboxone Tablet, and Subutex Tablet, which are designed to help individuals manage opioid withdrawal symptoms and reduce cravings. Indivior operates across three primary geographical segments: the United States, the United Kingdom, and the Rest of World, reflecting its global reach and commitment to addressing addiction on an international scale. Indivior's strategic focus on opioid dependence treatment positions it within a critical segment of the healthcare industry, addressing a significant public health challenge. The company's financial performance, marked by a profit margin of 19.4% and a gross margin of 83.1%, underscores its ability to maintain profitability while investing in research and development. Indivior's evolution from its founding to its current market position reflects its dedication to providing evidence-based treatments for addiction and improving patient outcomes.

What Products and Services Does INDV Offer?

• Develops buprenorphine-based prescription drugs for opioid dependence.
• Manufactures medications like Suboxone Film, Suboxone Tablet, and Subutex Tablet.
• Sells its products in the United States, United Kingdom, and other international markets.
• Focuses on treating opioid dependence and related substance use disorders.
• Conducts research and development to create new addiction treatments.
• Works with healthcare providers to improve access to addiction treatment.
• Engages in advocacy and awareness initiatives related to opioid dependence.

How Does INDV Make Money?

• Develops and patents proprietary formulations of buprenorphine-based medications.
• Manufactures and distributes its products through established pharmaceutical supply chains.
• Generates revenue through the sale of prescription drugs to healthcare providers and pharmacies.
• Invests in research and development to expand its product pipeline and improve existing treatments.

What Industry Does INDV Operate In?

Indivior Pharmaceuticals Inc. operates within the specialty pharmaceutical industry, focusing on treatments for opioid dependence. The market for addiction treatment is driven by increasing awareness of opioid abuse and the need for effective therapies. The competitive landscape includes companies like Amneal Pharmaceuticals, Inc. (AMRX) and Lantheus Holdings, Inc. (LNTH), which offer alternative treatments and generic options. The industry is subject to regulatory scrutiny and evolving treatment guidelines, impacting market access and pricing. Indivior's focus on buprenorphine-based medications positions it as a key player in addressing the opioid crisis, with growth potential tied to expanding its product pipeline and geographic reach.

Who Are INDV's Key Customers?

• Healthcare providers who prescribe medications for opioid dependence.
• Pharmacies that dispense Indivior's products to patients.
• Patients seeking treatment for opioid dependence and related disorders.
• Hospitals and clinics that offer addiction treatment services.

Over the past six months, Indivior PLC insiders filed 16 SEC Form 4 transactions — 6 sales and 10 purchases. On net that is roughly 634K shares disposed (about $26.2M), a signal worth weighing alongside the fundamentals.

Quarterly Financial Performance: Indivior PLC

Revenue for Indivior PLC came in at $343.0M during Q2 FY2026, a 8.2% improvement versus the preceding quarter. The company recorded net income of $122.0M, with diluted EPS of $0.95. Quarter-over-quarter revenue has been mixed, typical for a mid-cap company operating in Healthcare. Across the four most recent quarters, INDV averaged $0.69 in diluted EPS.

INDV Valuation & Market Position

With a $4.27B market cap, Indivior PLC sits in the mid-cap segment of the market. Analyst price targets span from $43.00 to $53.00, with a consensus of $48.00. At the current price of $34.23, that implies approximately 40% upside potential. Relative to its peer group, INDV's quantitative score of 58/100 is roughly in line with the peer average of 67/100.

Return on assets is 21.0%, showing how much profit it generates from its asset base. INDV trades at a trailing price-to-earnings ratio of 12.15, below the Healthcare sector average of ~21.50x. Its free cash flow yield is -3.6%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.86 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is 4.9%, the inverse of the P/E and a quick read on earnings relative to price.

Indivior PLC's Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of 3.48 places it in the safe zone, indicating low near-term bankruptcy risk.

Indivior PLC has beaten Wall Street's EPS estimate in 7 of its last 8 reported quarters — a consistent record of delivering on expectations. Reported results have landed about 56.8% above estimates on average.

Company Profile

Indivior PLC operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in North Chesterfield, US. The company is led by CEO Joseph J. Ciaffoni. INDV has traded publicly since 2014.

INDV Financials

INDV Latest News

INDV Analyst Consensus

INDV MoonshotScore

Latest Indivior PLC Analysis

Indivior PLC Healthcare Stock: Key Questions Answered

Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.

Official Resources